Wendy McCallum1, Hocine Tighiouart2, Jeffrey M Testani3, Matthew Griffin3, Marvin A Konstam4, James E Udelson4, Mark J Sarnak5. 1. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. 2. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. 3. Division of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut. 4. Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts. 5. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. Electronic address: msarnak@tuftsmedicalcenter.org.
Abstract
OBJECTIVES: This study aimed to examine whether incorporation of a comprehensive set of measures of decongestion modifies the association of acute declines in kidney function with outcomes. BACKGROUND: In-hospital acute declines in kidney function occur in approximately 20% to 30% of patients admitted with acute decompensated heart failure (ADHF) and may be associated with adverse outcomes. METHODS: Using data from EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan), we used multivariable Cox regression models to evaluate the association between in-hospital changes in estimated glomerular filtration rate (eGFR) with death and a composite outcome of cardiovascular death and hospitalization for heart failure. We evaluated eGFR declines within the context of changes in markers of volume overload including b-type natriuretic peptide (BNP), N-terminal prohormone of B-type natriuretic peptide (NT-proBNP), and weight, as well as changes in measures of hemoconcentration including hematocrit, albumin, and total protein. RESULTS: Among 3,715 patients over a median follow-up of 9.9 months, every 30% decline in eGFR was associated with higher risk of both death (hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 1.07 to 1.31) and the composite outcome (HR: 1.09; 95% CI: 1.01 to 1.18) in adjusted models. The acute decline in eGFR was no longer associated with higher risk of either outcome as long as there was evidence of decongestion, either by declines in BNP, NT-proBNP, or weight or by increases in hematocrit, albumin or total protein. Interaction testing between decline in eGFR and changes in hematocrit, albumin, and total protein was statistically significant (p interaction of <0.01 for death and p interaction of ≤0.01 for composite for all 3 biomarkers). Interaction between change in eGFR and changes in BNP (p interaction = 0.07 for death; p interaction = 0.08 for composite), NT-proBNP (p interaction = 0.15 for death; p interaction = 0.18 for composite) and weight (p interaction = 0.13 for death; p interaction = 0.19 for composite) did not meet statistical significance. CONCLUSIONS: Overall, acute declines in eGFR are associated with adverse outcomes, with evidence of modification by changes in markers of decongestion, suggesting that they are no longer associated with adverse outcomes if these markers are concomitantly improving.
OBJECTIVES: This study aimed to examine whether incorporation of a comprehensive set of measures of decongestion modifies the association of acute declines in kidney function with outcomes. BACKGROUND: In-hospital acute declines in kidney function occur in approximately 20% to 30% of patients admitted with acute decompensated heart failure (ADHF) and may be associated with adverse outcomes. METHODS: Using data from EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan), we used multivariable Cox regression models to evaluate the association between in-hospital changes in estimated glomerular filtration rate (eGFR) with death and a composite outcome of cardiovascular death and hospitalization for heart failure. We evaluated eGFR declines within the context of changes in markers of volume overload including b-type natriuretic peptide (BNP), N-terminal prohormone of B-type natriuretic peptide (NT-proBNP), and weight, as well as changes in measures of hemoconcentration including hematocrit, albumin, and total protein. RESULTS: Among 3,715 patients over a median follow-up of 9.9 months, every 30% decline in eGFR was associated with higher risk of both death (hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 1.07 to 1.31) and the composite outcome (HR: 1.09; 95% CI: 1.01 to 1.18) in adjusted models. The acute decline in eGFR was no longer associated with higher risk of either outcome as long as there was evidence of decongestion, either by declines in BNP, NT-proBNP, or weight or by increases in hematocrit, albumin or total protein. Interaction testing between decline in eGFR and changes in hematocrit, albumin, and total protein was statistically significant (p interaction of <0.01 for death and p interaction of ≤0.01 for composite for all 3 biomarkers). Interaction between change in eGFR and changes in BNP (p interaction = 0.07 for death; p interaction = 0.08 for composite), NT-proBNP (p interaction = 0.15 for death; p interaction = 0.18 for composite) and weight (p interaction = 0.13 for death; p interaction = 0.19 for composite) did not meet statistical significance. CONCLUSIONS: Overall, acute declines in eGFR are associated with adverse outcomes, with evidence of modification by changes in markers of decongestion, suggesting that they are no longer associated with adverse outcomes if these markers are concomitantly improving.
Authors: Wendy E Boertien; Esther Meijer; Paul E de Jong; Stephan J L Bakker; Frank S Czerwiec; Joachim Struck; Dorothee Oberdhan; Susan E Shoaf; Holly B Krasa; Ron T Gansevoort Journal: Kidney Int Date: 2013-07-31 Impact factor: 10.612
Authors: Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Jeffrey M Testani; Jennifer Chen; Brian D McCauley; Stephen E Kimmel; Richard P Shannon Journal: Circulation Date: 2010-07-06 Impact factor: 29.690
Authors: Kevin Damman; Gerjan Navis; Adriaan A Voors; Folkert W Asselbergs; Tom D J Smilde; John G F Cleland; Dirk J van Veldhuisen; Hans L Hillege Journal: J Card Fail Date: 2007-10 Impact factor: 5.712
Authors: Sergio Manzano-Fernández; Pedro J Flores-Blanco; Juan I Pérez-Calvo; Francisco J Ruiz-Ruiz; Francisco J Carrasco-Sánchez; José L Morales-Rull; Luis Galisteo-Almeda; Domingo Pascual-Figal; Mariano Valdes; James L Januzzi Journal: J Card Fail Date: 2013-08 Impact factor: 5.712
Authors: Marco Metra; Gad Cotter; Stefanie Senger; Christopher Edwards; John G Cleland; Piotr Ponikowski; Guillermo C Cursack; Olga Milo; John R Teerlink; Michael M Givertz; Christopher M O'Connor; Howard C Dittrich; Daniel M Bloomfield; Adriaan A Voors; Beth A Davison Journal: Circ Heart Fail Date: 2018-05 Impact factor: 8.790
Authors: Wendy McCallum; Hocine Tighiouart; Jeffrey M Testani; Matthew Griffin; Marvin A Konstam; James E Udelson; Mark J Sarnak Journal: Am J Kidney Dis Date: 2021-11-27 Impact factor: 11.072
Authors: Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2021-10-10 Impact factor: 17.349
Authors: Saif Ali; Sharon Jung; Shuktika Nandkeolyar; Liset Stoletniy; Antoine Sakr; Frederik H Verbrugge; Anthony Hilliard; Dmitry Abramov Journal: Am J Cardiovasc Drugs Date: 2021-03-12 Impact factor: 3.571
Authors: Johanna E Emmens; Jozine M Ter Maaten; Yuya Matsue; Sylwia M Figarska; Iziah E Sama; Gad Cotter; John G F Cleland; Beth A Davison; G Michael Felker; Michael M Givertz; Barry Greenberg; Peter S Pang; Thomas Severin; Claudio Gimpelewicz; Marco Metra; Adriaan A Voors; John R Teerlink Journal: Eur J Heart Fail Date: 2021-12-02 Impact factor: 17.349
Authors: Alberto Palazzuoli; Federico Crescenzi; Lorenzo Luschi; Angelica Brazzi; Mauro Feola; Arianna Rossi; Antonio Pagliaro; Nicolò Ghionzoli; Gaetano Ruocco Journal: Front Cardiovasc Med Date: 2022-03-07